[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-335525-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-335525-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","current-biological-implications-and-clinical-relevance-of-metastatic-circulating-tumor-cells","Current biological implications and clinical relevance of metastatic circulating tumor cells","","Metastatic disease and cancer recurrence drive most cancer-related deaths. Circulating tumor cells (CTCs) and disseminated tumor cells (DTCs) are central to cancer spread, making them key targets for diagnosis and monitoring. Liquid biopsy based on rare CTCs offers a minimally invasive route for early detection and better tumor management. Clinical translation requires precise CTC isolation from blood using biophysical properties, followed by molecular profiling via single-cell multi-omics to reveal tumor heterogeneity. Understanding CTC origin, morphology, and interactions with primary and metastatic niches and immune regulation can support future CTC-targeting trials.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/current-biological-implications-and-clinical-relevance-of-metastatic-circulating-tumor-cells/335525/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/current-biological-implications-and-clinical-relevance-of-metastatic-circulating-tumor-cells/335525.png","ImageObject",300,407,{"name":42,"@type":43},"Quinn","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are metastatic circulating tumor cells important in cancer outcomes?","Question",{"text":63,"@type":64},"Metastatic disease and cancer recurrence are major causes of cancer-related deaths, and CTCs/DTCs are driving forces behind cancer spread.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What is required before liquid biopsy can be used clinically?",{"text":68,"@type":64},"Before blood-sample analysis and clinical translation, CTCs must be precisely isolated from patients’ blood based on biophysical properties, followed by molecular identification using single-cell multi-omics.",{"name":70,"@type":61,"acceptedAnswer":71},"How do CTCs survive in the bloodstream despite mechanical stress and immune responses?",{"text":72,"@type":64},"Most CTCs die early, but surviving cells can activate immune-evasion pathways and form cluster phenotypes that help resist antitumor immune attacks and support metastasis.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},335525,1790148961,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":4},962075114765,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Clinical and Experimental Medicine (2025) 25:7  \n[https://doi.org/10.1007/s10238-024-01518-6](https://doi.org/10.1007/s10238-024-01518-6)  \nCurrent biological implications and clinical relevance of metastatic circulating tumor cells  \nReza Shahhosseini1 · SeyedAbbas Pakmehr2,3 · Anis Elhami2 · Maha Noori Shakir4 · Abdullah Ali Alzahrani5 · Mais Mazin Al‑Hamdani6 · Munther Abosoda7,8,9 · Ali Alsalamy10 · Majid Mohammadi‑Dehcheshmeh11 · Tahereh Ezazi Maleki12 · Hossein Saffarfar13 · Payam Ali‑Khiavi14  \nReceived: 9 October 2024 / Accepted: 4 November 2024 / Published online: 15 November 2024 © The Author(s) 2024  \nAbstract  \nMetastatic disease and cancer recurrence are the primary causes of cancer-related deaths. Circulating tumor cells (CTCs) and disseminated tumor cells (DTCs) are the driving forces behind the spread of cancer cells. The emergence and development of liquid biopsy using rare CTCs as a minimally invasive strategy for early-stage tumor detection and improved tumor management is a promising advancement in recent years. However, before blood sample analysis and clinical translation, precise isolation of CTCs from patients’ blood based on their biophysical properties, followed by molecular identification of CTCs using single-cell multi-omics technologies is necessary to understand tumor heterogeneity and provide effective diagnosis and monitoring of cancer progression. Additionally, understanding the origin, morphological variation, and interaction between CTCs and the primary and metastatic tumor niche, as well as and regulatory immune cells, will offer new insights into the development of CTC-based advanced tumor targeting in the future clinical trials.  \nGraphical Abstract  \nKeywords Cancer metastasis · Circulating tumor cells · Disseminated tumor cells · Liquid biopsy · Targeted therapy  \nReza Shahhosseini and SeyedAbbas Pakmehr have contributed equally to this work and share first authorship.  \nExtended author information available on the last page of the article  \nBackground  \nIn 2024, it is projected to be 2,001,140 new cases of cancer and 611,720 deaths from cancer in the USA. Incidence rates for cancers of the breast, pancreas, and uterus increased by 0.6–1% per year between 2015 and 2019. For cancers of the prostate, liver, kidney, human papillomavirus-associated oral cancers, and melanoma, the rate increased by 2–3% per year [1]. Despite advances in cancer treatment, metastasis is still the number one cause of death from cancer around the world [2] . Metastasis is the primary factor causing mortality in colorectal cancer (CRC) [3] and breast cancer patients [4] . A significant barrier to improving outcomes in patient with advanced solid tumor is the limited ability of current clinical diagnostic tools to predict metastasis and detect minimal residual disease (MRD) [5] . This is often the case due to inadequate diagnostic cutoffs, sampling biases caused by tumor tissue or biomarker heterogeneity and limited sampling of metastases [6] . Moving forward, oncologists have introduced liquid biopsy using blood samples from tumors as an alternative, real-time, and minimally invasive method for early detection, prognosis, and prediction of response to anticancer drugs [7] . Tumor-derived blood samples contain analytes such as circulating tumor cells (CTCs), cell-free DNA (cfDNA), cell-free RNA (cfRNA), and exosomes that provide a promising tool for tailoring the management of each patient with advanced cancers [8, 9] .  \nNaturally, invasive primary tumors and metastatic tumors shed CTCs into the bloodstream to seed distant secondary sites and induce metastases. Therefore, isolating CTCs from blood samples using technological tools and analyzing them according to their established cutoff number and molecular profile could be interesting biomarkers for monitoring cancer patients [10]. In addition, targeting CTCs in vivo provides more opportunities to expand their clinical utility in the field of cancer treatment [11","cbCaijg0YMsKAw8O","https://ap.wps.com/l/cbCaijg0YMsKAw8O","pdf",1257068,13,"English","# Abstract\n## Background\n## CTC biology and tumor metastases","[{\"question\":\"Why are metastatic circulating tumor cells important in cancer outcomes?\",\"answer\":\"Metastatic disease and cancer recurrence are major causes of cancer-related deaths, and CTCs/DTCs are driving forces behind cancer spread.\"},{\"question\":\"What is required before liquid biopsy can be used clinically?\",\"answer\":\"Before blood-sample analysis and clinical translation, CTCs must be precisely isolated from patients’ blood based on biophysical properties, followed by molecular identification using single-cell multi-omics.\"},{\"question\":\"How do CTCs survive in the bloodstream despite mechanical stress and immune responses?\",\"answer\":\"Most CTCs die early, but surviving cells can activate immune-evasion pathways and form cluster phenotypes that help resist antitumor immune attacks and support metastasis.\"}]","Current biological implications and clinical relevance of metastatic circulating tumor cells | PDF",1790011305,33]